Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Velocity-Based Resistance Training Effects on Inflammation in Older Adults

4. mai 2026 oppdatert av: National Taipei University

Dose-Response Effects of Velocity-Based Resistance Training on Anti-Inflammatory Responses in Older Adults

This study aims to investigate the effects of resistance training (RT) with different training volumes on immune modulation and anti-inflammatory responses in older adults. Participants will be randomly assigned to one of three RT volume groups (low, medium, or high) or a non-exercise control group. Participants in the training groups will complete a 4-week RT program, followed by a 4-week detraining phase. The findings are expected to provide evidence for volume-specific RT prescriptions to support healthy aging.

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Antatt)

60

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

  • Taiwan
      • Taipei, Taiwan, 116
        • Rekruttering
        • National Taiwan Normal University
        • Ta kontakt med:
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Ja

Beskrivelse

Inclusion Criteria:

  • Aged 60-75 years or older
  • No regular resistance training habit (defined as ≥2 sessions per week) in the past year
  • No musculoskeletal injuries within the past six months

Exclusion Criteria:

  • Obesity (BMI > 30 kg/m²), diabetes, hypertension, cancer, heart, kidney, or liver disease, or any other condition that may influence study outcomes.
  • Regular use of anti-inflammatory medications (e.g., NSAIDs).
  • Smoking or alcohol abuse
  • Inability to safely perform the prescribed resistance exercise movements
  • Unable to fully comprehend the study information and instructions.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Crossover-oppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: low training volume resistance exercise
Participants assigned to the low-volume resistance training group will perform one set per exercise at a load corresponding to 80% of 1RM. Each set will be terminated when movement velocity decreases by 30% from the first repetition. Rest intervals of 2-3 minutes will be provided between exercises.
Annen: Resistance exercise
The RT program will consist of 12 sessions over a 4-week period, with participants training three times per week and at least one rest day between sessions. All sessions will be supervised by research personnel to ensure proper technique and safety. Exercises will be performed using resistance machines and will include chest press, shoulder press, seated row, lat pulldown, and leg press.
Eksperimentell: medium training volume resistance exercise
Participants assigned to the medium-volume resistance training group will perform three sets per exercise at 80% of 1RM. Each set will be terminated when movement velocity decreases by 30% relative to the first repetition. Rest intervals of 90 seconds will be provided between sets, and 2-3 minutes between exercises.
Annen: Resistance exercise
The RT program will consist of 12 sessions over a 4-week period, with participants training three times per week and at least one rest day between sessions. All sessions will be supervised by research personnel to ensure proper technique and safety. Exercises will be performed using resistance machines and will include chest press, shoulder press, seated row, lat pulldown, and leg press.
Eksperimentell: high training volume resistance exercise
Participants assigned to the high-volume resistance training group will perform five sets per exercise at 80% of 1RM. Each set will be terminated when movement velocity decreases by 30% relative to the first repetition. Rest intervals of 90 seconds will be provided between sets, and 2-3 minutes between exercises.
Annen: Resistance exercise
The RT program will consist of 12 sessions over a 4-week period, with participants training three times per week and at least one rest day between sessions. All sessions will be supervised by research personnel to ensure proper technique and safety. Exercises will be performed using resistance machines and will include chest press, shoulder press, seated row, lat pulldown, and leg press.
Ingen inngripen: sedentary control
Participants in control trial stayed sedentary during the period.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Changes in IL-6 concentration
Tidsramme: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Plasma IL-6 concentrations will be measured and reported in pg/mL.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in soluble IL-6 receptor concentration
Tidsramme: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Soluble IL-6 receptor concentrations will be measured and reported in ng/mL.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in soluble gp130 concentration
Tidsramme: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Soluble gp130 concentrations will be measured and reported in ng/mL.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in IL-10 concentration
Tidsramme: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
IL-10 concentrations will be measured and reported in pg/mL.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in IL-1RA concentration
Tidsramme: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
IL-1RA concentrations will be measured and reported in pg/mL.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in TNF-α concentration
Tidsramme: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
TNF-α concentrations will be measured and reported in pg/mL.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Borgs Ratings of Perceived Exertion (RPE)
Tidsramme: 1-hour during each exercise intervention
Borgs RPE is a method of estimating exertion rating, based on a 1 to 10 rating scale (1 being the no exertion at all, 10 being maximal exertion).
1-hour during each exercise intervention
Handgrip strength
Tidsramme: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Maximal handgrip strength will be assessed using a digital hand dynamometer and reported in kilograms.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Knee extension strength
Tidsramme: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Maximal voluntary isometric and isokinetic concentric knee extension strength of the dominant leg will be assessed using an isokinetic dynamometer and reported in Newton-meters.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
30-second chair-stand test
Tidsramme: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Lower-body functional capacity will be assessed by the number of repetitions completed during a 30-second chair-stand test.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Single-leg balance test
Tidsramme: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Balance performance will be assessed as the duration of single-leg stance and reported in seconds.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Timed up and go test
Tidsramme: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Functional mobility will be assessed using the Timed Up and Go test, with performance quantified as the time (seconds) required to stand up from a seated position, walk 3 meters, turn, walk back, and sit down.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in SHIP1 protein expression in peripheral blood mononuclear cells (PBMCs)
Tidsramme: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Intracellular SHIP1 protein expression in PBMCs will be measured and reported in arbitrary units.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in gp130 (CD130) protein expression in PBMCs
Tidsramme: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Intracellular gp130 (CD130) protein expression in PBMCs will be measured and reported in arbitrary units.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in STAT3 protein expression in PBMCs
Tidsramme: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Intracellular STAT3 protein expression in PBMCs will be measured and reported in arbitrary units.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in phosphorylated STAT3 protein expression in PBMCs
Tidsramme: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Intracellular phosphorylated STAT3 (p-STAT3) protein expression in PBMCs will be measured and reported in arbitrary units.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in IL-6 receptor alpha (CD126) protein expression in PBMCs
Tidsramme: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Intracellular IL-6 receptor alpha (CD126) protein expression in PBMCs will be measured and reported in arbitrary units.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in Beta-2 adrenergic receptor (β2-AR) protein expression in PBMCs
Tidsramme: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Intracellular β2-adrenergic receptor (β2-AR) protein expression in PBMCs will be measured and reported in arbitrary units.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in SOCS3 protein expression in PBMCs
Tidsramme: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Intracellular SOCS3 protein expression in PBMCs will be measured and reported in arbitrary units.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in white blood cell count
Tidsramme: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Total white blood cell count will be measured and reported in cells/μL.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in lymphocyte count
Tidsramme: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Lymphocyte count will be measured and reported in cells/μL.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in neutrophil count
Tidsramme: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Neutrophil count will be measured and reported in cells/μL.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in monocyte count
Tidsramme: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Monocyte count will be measured and reported in cells/μL.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Body fat percentage
Tidsramme: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Body fat percentage will be measured using a body composition analyzer and reported as a percentage.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Lean body mass
Tidsramme: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Total lean body mass will be measured using a body composition analyzer and reported in kilograms.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

National Taipei University

Etterforskere

  • Hovedetterforsker: Shun-Hsi Tsai, Ph.D., National Taipei University

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

20. april 2026

Primær fullføring (Antatt)

1. mars 2029

Studiet fullført (Antatt)

1. desember 2029

Datoer for studieregistrering

Først innsendt

15. april 2026

Først innsendt som oppfylte QC-kriteriene

28. april 2026

Først lagt ut (Faktiske)

5. mai 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

8. mai 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

4. mai 2026

Sist bekreftet

1. april 2026

Mer informasjon

Begreper knyttet til denne studien

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • ECKIRB1140803

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Kliniske studier på Inflammatorisk respons

Søk i lignende forsøk

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

CROs by country

CROs in Kuwait

Forhold

Sjeldne sykdommer

Legemiddelintervensjoner

Kosttilskudd

Sponsor / samarbeidspartnere

Steder

Abonnere